Anteris talks market superiority of its biomimetic TAVR valve
–News Direct–
Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson speaks with Proactive after the successful completion of enrolment for the companys early feasibility study (EFS) to evaluate DurAVR THV. This unique device represents a new class of biomimetic valve and stands as the world's only balloon-expandable, single-piece transcatheter aortic valve. The study aims to assess the safety and feasibility of DurAVR THV in treating 15 patients suffering from symptomatic, severe native aortic stenosis, and is critical to obtaining US Food and Drug Administration clearance.
Anteris is a structural heart company committed to designing, developing, and commercialising innovative medical devices. Founded in Australia, with a significant presence in Minneapolis, USA (a MedT...